Last reviewed · How we verify
NCT03752489
Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment
Phase 2 trial testing Treatment-specific InSight in Sepsis in 51,645 participants. Status unknown.
31 March 2024
Quick facts
| Lead sponsor | Dascena |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | diagnostic |
| Enrollment | 51,645 |
| Start date | 1 April 2022 |
| Primary completion | 31 March 2024 |
| Estimated completion | 31 March 2024 |
Drugs / interventions tested
- Treatment-specific InSight
- InSight
Conditions studied
- Sepsis — all drugs for Sepsis →
- Severe Sepsis — all drugs for Severe Sepsis →
- Septic Shock — all drugs for Septic Shock →
Sponsor
Dascena
Who can join
18 and older, any sex, with Sepsis or Severe Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The focus of this study will be to conduct a prospective, randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a fluid treatment-specific algorithm will be applied to EHR data for the detection of severe sepsis. For patients determined to have a high risk of severe sepsis, the algorithm will generate automated voice, telephone notification to nursing staff at CRMC, OH, and UCSF. The algorithm's performance will be measured by analysis of the primary endpoint, reductions in in-hospital mortality.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03752489
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other Dascena trials
Trials by the same sponsor.
- NCT03734484 — Gram Type Infection-Specific Sepsis Identification Using Machine Learning · Phase 2 · withdrawn
- NCT04005001 — Machine Learning Sepsis Alert Notification Using Clinical Data · Phase 2 · unknown
- NCT04358510 — COVID-19 Mortality Prediction Model · completed
- NCT04358536 — Classification of COVID-19 Infection in Posteroanterior Chest X-rays · completed
- NCT04390516 — Respiratory Decompensation and Model for the Triage of COVID-19 Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03752489 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dascena
- Last refreshed: 23 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03752489.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing